Skip to main content
. 2018 Feb 12;128(3):1043–1056. doi: 10.1172/JCI94996

Figure 5. Nisoldipine reveals increased ICaL sensitivity in severely affected iPSC-CMs.

Figure 5

(AE) The effect of 0.05 μM nisoldipine on both trios. Data are depicted as macroscopic action potential record, APD summary data, and ICaL comparison between no drug and nisoldipine. Between 8 and 11 cells were analyzed for the effects of nisoldipine on APD and 5–8 cells for the effects of nisoldipine on ICaL in AE. See Supplemental Table 4 for exact numbers of replicate measures (n) and statistical analysis (paired Student’s t test). Dose-response relationship for nisoldipine (Supplemental Figure 1) was determined before selection of the concentration used in these experiments (a concentration lower than EC50 was chosen because the objective was to shorten the APD and ICaL to levels more like those of control iPSC-CMs). *P < 0.05; as determined by paired 2-tailed Student’s t test.